INOCA/ANOCA:机制和新型治疗方法
Namrita D Ashokprabhu1,2,3, Odayme Quesada1,2,3, Yulith Roca Alvarez1,2,3
1Women's Heart Center at The Christ Hospital, Cincinnati, OH, USA.
概括
没有阻塞性冠状动脉疾病 (ANOCA/INOCA) 的胸痛或缺血通常未得到充分治疗. 冠状动脉微血管功能障碍 (CMD) 是一个关键原因,新的诊断工具和疗法正在出现.
科学领域:
- 心脏病学 心脏病学
- 血管生物学 血管生物学
- 诊断成像 诊断成像 诊断成像
背景情况:
- 没有阻塞性冠状动脉疾病 (ANOCA/INOCA) 的胸痛或缺血症,由于了解不充分的机制和有限的治疗选择,具有重大临床挑战.
- 冠状动脉微血管功能障碍 (CMD) 是ANOCA/INOCA的主要贡献者,其特点是肌心 perfusion 不足.
- 目前的治疗依赖于一般的抗血管性药物,氨酸-血管激素系统抑制剂和他类药物,强调了针对性治疗的必要性.
研究的目的:
- 在ANOCA/INOCA中审查目前对CMD病理生理学的理解.
- 讨论用于识别CMD的可用诊断工具.
- 探索和开发ANOCA/INOCA的新型治疗策略.
主要方法:
- 冠状动脉功能血管学 (CFA) 用于评估内皮独立和内皮依赖的微血管功能.
- CFA评估冠状动脉流量减少对腺和微血管/心脏对乙胆的反应.
- 对现有的病理生理学,诊断和新兴CMD治疗方法的文献进行审查.
主要成果:
- CFA可以识别内皮细胞独立的微血管功能障碍 (冠状动脉流量减少<2.5) 和内皮细胞依赖的功能障碍 (改变血管扩张/收缩).
- 这项研究强调了微血管在ANOCA/INOCA中的作用.
- 几种新疗法正在研究中,包括冠状动脉鼻减小剂,干细胞疗法和新的药理学药物.
结论:
- 在ANOCA/INOCA中,CMD是关键因素,需要改进诊断和治疗方法.
- 冠状动脉功能血管学为微血管功能提供了有价值的见解.
- 新兴疗法显示出在ANOCA/INOCA中解决CMD潜在病理学的前景.
相关概念视频
01:23Local Anesthetics: Mechanism of Action
2.3K
Local anesthetics (LAs) block sensory and motor impulses by inhibiting the sodium channels on the nerve cell membranes. This induces temporary loss of sensation, relieving pain in a specific body area.
Local anesthetics are amphiphilic molecules consisting of a hydrophobic aromatic part linked to a hydrophilic group by an ester or amide linkage. They are weak bases and are usually available as salts, which increases their solubility and stability. Once administered, LAs exist in the body either...
Local anesthetics are amphiphilic molecules consisting of a hydrophobic aromatic part linked to a hydrophilic group by an ester or amide linkage. They are weak bases and are usually available as salts, which increases their solubility and stability. Once administered, LAs exist in the body either...
2.3K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
155
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
155
01:27Open Angle Glaucoma: Treatment
481
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
481
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
201
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
201
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
158
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
158
01:29Drugs for Treatment of Ulcerative Colitis in IBD
179
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
179